Veracyte reports Q2 2026 revenue $150.3M (+15% YoY), raises FY2026 guidance

Filed July 30, 2026 · Period ending July 30, 2026 · ~1 min read

Key Changes

• high

  Q2 2026 total revenue $150.3M (+15% YoY), testing revenue $145.7M (+19%); Decipher $91.9M (+20%), Afirma $51.2M (+18%). Test volume up 13% to 50,967 tests.

  Exhibit 99.1 view on EDGAR →
• high

  GAAP net income $25.5M (17.0% margin), adjusted EBITDA $44.0M (29.2% margin). Operating cash flow $45.8M; cash and investments $485.2M at quarter-end.

  Exhibit 99.1 view on EDGAR →
• high

  Raised FY2026 total revenue guidance to $590–$596M (14–15% growth) from $582–$592M; testing revenue to $576–$582M (17–18% growth) from $570–$580M. Maintained adjusted EBITDA margin target >26%.

  Exhibit 99.1 view on EDGAR →